Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

被引：0
|
作者：
Gandhi, L. [1 ]
Gadgeel, S. [2 ]
Shaw, A. [3 ]
Barlesi, F. [4 ]
Crino, L. [5 ]
Yang, J. C-H. [6 ,7 ]
Dingemans, A-M. C. [8 ]
Kim, D-W. [9 ]
de Marinis, F. [10 ]
Schulz, M. [11 ]
Liu, S. [11 ]
Fish, S. [11 ]
Kotb, A. [12 ]
Ou, S-H. I. [13 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[5] Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy
[6] Natl Taiwan Univ Hosp, Grad Inst Oncol, Taipei, Taiwan
[7] Natl Taiwan Univ Hosp, Canc Res Ctr, Taipei, Taiwan
[8] MUMC, Pulmonol, Maastricht, Netherlands
[9] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea
[10] European Inst Oncol, Thorac Inst Oncol, Milan, Italy
[11] Genentech Inc, US Med Affairs, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[12] F Hoffmann La Roche Ltd, Med Affairs, Basel, Switzerland
[13] Univ Calif Irvine, Med Oncol, Orange, CA 92668 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1209PD
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 2 Study of Ceritinib in Patients with ALK plus NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
    Horinouchi, H.
    Maemondo, M.
    Hida, T.
    Takeda, M.
    Hotta, K.
    Hirai, F.
    Kim, Y.
    Matsumoto, S.
    Mitsudomi, T.
    Seto, T.
    Moizumi, S.
    Tokushige, K.
    Hatano, B.
    Nishio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1951 - S1952
  • [22] CONSISTENT THERAPEUTIC EFFICACY OF CH5424802/RO5424802 IN BRAIN METASTASES AMONG CRIZOTINIB-REFRACTORY ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN AN ONGOING PHASE I/II STUDY (AF-002JG/NP28761, NCT01588028).
    Ou, Sai-Hong I.
    Gadgeel, Shirish
    Chiappori, Alberto A.
    Gandhi, Leena
    Azada, Michele
    Garcia, Linta
    Takaya, Itsumi
    Yokoyama, Shumpei
    Kamei, Tomonori
    Tanaka, Tomohiro
    Lee, Ruey-Min
    Riely, Gregory
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S200 - S200
  • [23] Alectinib exposure-response (ER) in ALK-inhibitor naive ALK-positive NSCLC patients: Pooled analysis across phase III studies.
    Smart, Kevin
    Hsu, Joy C.
    Jaminion, Felix
    Guerini, Elena
    Shaw, Alice Tsang
    Zhou, Caicun
    Mok, Tony S. K.
    Bordogna, Walter
    Frey, Nicolas
    Morcos, Peter N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC
    Leal, Ticiana
    Wakelee, Heather
    Infante, Jeffrey
    Blumenschein, George
    Reckamp, Karen
    Carter, Corey
    Waqar, Saiama
    Gockerman, Jon
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S209 - S210
  • [25] Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
    Gadgeel, Shirish
    Shaw, Alice T.
    Barlesi, Fabrice
    Crino, Lucio
    Yang, James Chih-Hsin
    Dingemans, Anne-Marie C.
    Kim, Dong-Wan
    de Marinis, Filippo
    Schulz, Mathias
    Liu, Shiyao
    Gupta, Ravindra
    Kotb, Ahmed
    Ou, Sai-Hong Ignatius
    BRITISH JOURNAL OF CANCER, 2018, 118 (01) : 38 - 42
  • [26] Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
    Shirish Gadgeel
    Alice T Shaw
    Fabrice Barlesi
    Lucio Crinò
    James Chih-Hsin Yang
    Anne-Marie C Dingemans
    Dong-Wan Kim
    Filippo de Marinis
    Mathias Schulz
    Shiyao Liu
    Ravindra Gupta
    Ahmed Kotb
    Sai-Hong Ignatius Ou
    British Journal of Cancer, 2018, 118 : 38 - 42
  • [27] Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
    Horn, Leora
    Wakelee, Heather
    Reckamp, Karen
    Blumenschein, George
    Infante, Jeffrey
    Carter, Corey
    Waqar, Saiama
    Neal, Joel
    Gockerman, Jon
    Harrow, Kimberly
    Dukart, Gary
    Liang, Chris
    Gibbons, James
    Hernandez, Jennifer
    Newman-Eerkes, Tera
    Lim, Lee
    Lovly, Christine
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1159 - S1159
  • [28] Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK plus NSCLC
    Horn, Leora
    Wakelee, Heather
    Reckamp, Karen L.
    Blumenschein, George, Jr.
    Infante, Jeffrey R.
    Carter, Corey A.
    Waqar, Saiama N.
    Nea, Joel W.
    Harrow, Kimberly
    Gockerman, Jon P.
    Dukart, Gary
    Liang, Chris
    Gibbons, James L.
    Hernandez, Jennifer
    Newman-Eerkes, Tera
    Lim, Lee
    Lovly, Christine M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S256 - S257
  • [29] Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study
    Cortot, A.
    Escande, F.
    Gervais, R.
    Greillier, L.
    Corre, R.
    Veillon, R.
    Ionescu, M.
    Felicio, H.
    Pau, D.
    Gregoire, V.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S658 - S658
  • [30] Circulating free DNA as a prognostic biomarker in patients with advanced ALK plus NSCLC treated with alectinib from the global phase III ALEX trial.
    Dziadziuszko, Rafal
    Peters, Solange
    Mok, Tony S. K.
    Camidge, D. Ross
    Noe, Johannes
    Nowicka, Malgorzata
    Bordogna, Walter
    Morcos, Peter N.
    Smoljanovic, Vlatka
    Tsang, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345